Cipher Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA17253X1050
CAD
16.70
-0.15 (-0.89%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

41.86 k

Shareholding (Sep 2024)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROE of 25.10%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.64

 
3

With a growth in Net Profit of 116.61%, the company declared Very Positive results in Jun 25

4

With ROE of 11.37%, it has a fair valuation with a 2.70 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 426 Million (Small Cap)

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

21.99%

stock-summary
Price to Book

2.46

Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Dec 2025)
Net Profit:
19 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.81%
0%
15.81%
6 Months
1.15%
0%
1.15%
1 Year
39.4%
0%
39.4%
2 Years
99.28%
0%
99.28%
3 Years
363.89%
0%
363.89%
4 Years
584.43%
0%
584.43%
5 Years
1695.7%
0%
1695.7%

Cipher Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
19.49%
EBIT Growth (5y)
7.12%
EBIT to Interest (avg)
12.64
Debt to EBITDA (avg)
0.38
Net Debt to Equity (avg)
0.17
Sales to Capital Employed (avg)
0.29
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
37.30%
ROE (avg)
25.10%

Valuation key factors

Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
2.46
EV to EBIT
18.40
EV to EBITDA
12.78
EV to Capital Employed
2.49
EV to Sales
6.00
PEG Ratio
0.08
Dividend Yield
NA
ROCE (Latest)
13.52%
ROE (Latest)
21.99%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -3.95% vs -4.32% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 144.74% vs -7.32% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17.00",
          "val2": "17.70",
          "chgp": "-3.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8.40",
          "val2": "9.30",
          "chgp": "-9.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "18.60",
          "val2": "7.60",
          "chgp": "144.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "343.90%",
          "val2": "387.60%",
          "chgp": "-4.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 54.27% vs 59.79% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 141.77% vs -42.55% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "70.50",
          "val2": "45.70",
          "chgp": "54.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "33.20",
          "val2": "12.50",
          "chgp": "165.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "38.20",
          "val2": "15.80",
          "chgp": "141.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "327.30%",
          "val2": "153.90%",
          "chgp": "17.34%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
17.00
17.70
-3.95%
Operating Profit (PBDIT) excl Other Income
8.40
9.30
-9.68%
Interest
0.20
0.30
-33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
18.60
7.60
144.74%
Operating Profit Margin (Excl OI)
343.90%
387.60%
-4.37%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -3.95% vs -4.32% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 144.74% vs -7.32% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
70.50
45.70
54.27%
Operating Profit (PBDIT) excl Other Income
33.20
12.50
165.60%
Interest
1.60
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
38.20
15.80
141.77%
Operating Profit Margin (Excl OI)
327.30%
153.90%
17.34%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 54.27% vs 59.79% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 141.77% vs -42.55% in Dec 2024

stock-summaryCompany CV
About Cipher Pharmaceuticals, Inc. stock-summary
stock-summary
Cipher Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Company Coordinates stock-summary
Company Details
209 Oak Park Blvd, Suite 501 , OAKVILLE ON : L6H 0M2
stock-summary
Tel: 1 905 60258401 416 5199442
stock-summary
Registrar Details